A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single-Agent Belantamab Mafodotin (Belamaf) Compared With Pomalidomide Plus Low-Dose Dexamethasone (Pd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (DREAMM-3)

被引：0

作者：

Weisel, Katja ^{[1
]}

Hungria, Vania T. M. ^{[2
]}

Radinoff, Atanas ^{[3
]}

Delimpasi, Sosana ^{[4
]}

Gabor, Mikala ^{[5
]}

Masszi, Tamas ^{[6
]}

Li, Jian ^{[7
]}

Capra, Marcelo ^{[8
]}

Matsumoto, Morio ^{[9
]}

Sule, Neal ^{[10
]}

Li, Mary ^{[10
]}

McKeown, Astrid ^{[11
]}

He, Wei ^{[12
]}

Bright, Shelley ^{[10
]}

Currie, Brooke ^{[13
]}

Boyle, Julia ^{[14
]}

Opalinska, Joanna ^{[10
]}

Dimopoulos, Meletios Athanasios ^{[15
]}

机构：

[1] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany

[2] Dept Hematol, Clin Sao Germano, Sao Paulo, Brazil

[3] Univ Hosp St Ivan Rilski EAD, Sofia, Bulgaria

[4] Gen Hosp Evangelismos, Athens, Greece

[5] Natl Inst Haematol & Infect Dis, South Pest Cent Hosp, Budapest, Hungary

[6] Semmelweis Univ, Dept Internal Med & Haematol, Budapest, Hungary

[7] Chinese Acad Med Sci & Peking Union Med Coll, Dept Hematol, Peking Union Med Coll Hosp, Beijing, Peoples R China

[8] Hosp Mae Deus, Ctr Integrado Hematol & Oncol, Porto Alegre, RS, Brazil

[9] Natl Hosp Org, Shibukawa Med Ctr, Shibukawa, Japan

[10] GSK, Upper Providence, PA USA

[11] GSK, Stevenage, Herts, England

[12] GSK, Waltham, MA USA

[13] GSK, Rockville, MD USA

[14] GSK, London, England

[15] Natl & Kapodistrian Univ Athens, Sch Med, Athens, Greece

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

multiple myeloma; belantamab mafodotin; relapsed/refractory multiple myeloma; phase III;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MM-509

引用

页码：S504 / S505

页数：2

共 50 条

[41] APOLLO: Phase 3 randomized study of subcutaneous Daratumumab plus Pomalidomide and Dexamethasone (D-Pd) versus Pomalidomide and Dexamethasone (Pd) alone in patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Einsele, H.
Dimopoulos, M.
Terpos, E.
Boccadoro, M.
Delimpasi, S.
Beksac, M.
Katodritou, E.
Moreau, P.
Baldini, L.
Symeonidis, A.
Bila, J.
Oriol, A.
Mateos, M. -, V
Orfanidis, I
Ahmadi, T.
Ukropec, J.
Kampfenkel, T.
Schecter, J.
Qiu, Y.
Amin, H.
Vermeulen, J.
Carson, R.
Sonneveld, P.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 178 - 178
[42] DREAMM 4: A phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)
Trudel, S.
Nooka, A.
Fecteau, D.
Talekar, M.
Jewell, R. C.
Williams, D.
Evans, J.
Opalinska, J.
ANNALS OF ONCOLOGY, 2019, 30
[43] Patient-Reported Outcomes From the DREAMM-7 Randomized Phase 3 Study Comparing Belantamab Mafodotin (Belamaf), Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Hungria, Vania
Robak, Pawel
Hus, Marek
Fu, ChengCheng
Zherebtsova, Vera
Ward, Christopher
de Almeida, Ana Carolina
Ho, P. Joy
Hajek, Roman
Cerchione, Claudio
Pirooz, Nick
McKeown, Astrid
Baig, Hena
Eccersley, Lydia
Pompilus, Farrah
McNamara, Simon
Lin, Chee Paul
Roy-Ghanta, Sumita
Opalinska, Joanna
Victoria Mateos, Maria
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S568 - S568
[44] Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
Pour, Ludek
Szarejko, Monika
Bila, Jelena
Schjesvold, Fredrik H.
Spicka, Ivan
Maisnar, Vladimir
Jurczyszyn, Artur
Grudeva-Popova, Zhanet
Hajek, Roman
Usenko, Ganna
Thuresson, Marcas
Norin, Stefan
Jarefors, Sara
Bakker, Nicolaas A.
Richardson, Paul G.
Mateos, Maria-Victoria
HAEMATOLOGICA, 2024, 109 (03) : 895 - 905
[45] Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).
Richardson, Paul G.
Perrot, Aurore
San-Miguel, Jesus F.
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Sy.
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Zheng, Cheng
Dubin, Franck
Van de Velde, Helgi
Anderson, Kenneth Carl
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[46] Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
San Miguel, Jesus
Weisel, Katja
Moreau, Philippe
Lacy, Martha
Song, Kevin
Delforge, Michel
Karlin, Lionel
Goldschmidt, Hartmut
Banos, Anne
Oriol, Albert
Alegre, Adrian
Chen, Christine
Cavo, Michele
Garderet, Laurent
Ivanova, Valentina
Martinez-Lopez, Joaquin
Belch, Andrew
Palumbo, Antonio
Schey, Stephen
Sonneveld, Pieter
Yu, Xin
Sternas, Lars
Jacques, Christian
Zaki, Mohamed
Dimopoulos, Meletios
LANCET ONCOLOGY, 2013, 14 (11): : 1055 - 1066
[47] Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study (vol 394, pg 2096, 2019)
Attal, M.
Richardson, P. G.
Rajkumar, S., V
LANCET, 2019, 394 (10214): : 2072 - 2072
[48] Updates from ICARIA-MM, a Phase 3 Study of Isatuximab (Isa) Plus Pomalidomide and Low-Dose Dexamethasone (Pd) vs Pd in Relapsed and Refractory Multiple Myeloma (RRMM)
Richardson, Paul G.
Perrot, Aurore
San-Miguel, Jesus
Beksac, Meral
Spicka, Ivan
Leleu, Xavier
Schjesvold, Fredrik
Moreau, Philippe
Dimopoulos, Meletios A.
Huang, Jeffrey Shang-Yi
Minarik, Jiri
Cavo, Michele
Prince, H. Miles
Zheng, Cheng
Dubin, Franck
van de Velde, Helgi
Anderson, Kenneth C.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S423 - S424
[49] LINKER-MM3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (EPd) in relapsed/refractory multiple myeloma (RRMM)
Weisel, Katja
Hungria, Vania
Quach, Hang
Yoon, Sung-Soo
Rodriguez-Otero, Paula
Sinha, Arijit
Boyapati, Anita
Lyon, Charlotte
Moore, Vygngley
Inocencio, Tim
Harnett, James
Chi, Lei
Lorenc, Karen Rodriguez
Kroog, Glenn
Voorhees, Peter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S63 - S64
[50] Recovery of Ocular Events with Longer-Term Follow-up in the DREAMMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Lonial, Sagar
Nooka, Ajay
Thulasi, Praneetha
Badros, Ashraf Z.
Jeng, Bennie H.
Callander, Natalie S.
Sborov, Douglas
Zaugg, Brian E.
Popat, Rakesh
Degli Esposti, Simona
Byrne, Julie
Opalinska, Joanna
Baron, January
Piontek, Trisha
Gupta, Ira
Dana, Reza
Farooq, Asim
Jakubowiak, Andrzej
BLOOD, 2020, 136

← 1 2 3 4 5 →